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The coexistence of CCND1/IGH and MYC rearrangements in mantle cell lymphoma (MCL) 
is a rare finding associated with a very poor prognosis. In this study, a patient with blastoid 
variant (MCL) is reported. The disease was clinically aggressive and refractory to chemo-
therapy, and the patient only survived for 1 month following diagnosis. Conventional cyto-
genetic study, FISH, and multicolor FISH (mFISH) demonstrated the involvement of the 
BCL1/CCND1 locus in a complex translocation, t(3;11)(q25;p15)t(11;14)(q13;q32). In addi-
tion, subclonal abnormalities in the 8q24 region, manifested as a t(8;14)(q24;q32)/MYC re-
arrangement, were identified. To the best of our knowledge, this is the first MCL case in 
Korea bearing these complex genomic aberrations. 
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INTRODUCTION
Mantle cell lymphoma (MCL) is a distinct subtype of mature B-
cell lymphoma, constituting 5-10% of all non-Hodgkin lymphoma 
cases. Patients with MCL have a poor prognosis, with a median 
survival of 3 to 5 yr. The blastoid variant of MCL occurs in 10-20% 
of all MCL patients, and a more aggressive clinical course has 
been reported in patients with this variant. MCL is typically posi-
tive for B-cell associated markers in addition to bcl-2, cyclin D1, 
CD5, and/or CD43 and is negative for bcl-6, CD10, and CD23 on 
immunohistochemistry [1, 2]. 
  The genetic hallmark of MCL, the translocation t(11;14)(q13; 
q32), juxtaposing the IGH on 14q32 with the BCL1/CCND1 gene 
on 11q13, results in constitutional overexpression of CCND1 and 
cell cycle dysregulation, in virtually all cases [3]. Although most 
CCND1/IGH gene rearrangements result from balanced translo-
cation t(11;14), complex variants of this translocation have been 
reported, involving additional partner chromosomes leading to 
various unbalanced translocations [4-6]. 
  It is believed that the overexpression of CCND1 is not, on its 
own, sufficient to induce malignant transformation of lymphoid 
cells. Molecular genetic studies have confirmed that additional 
genomic aberrations are found in the majority of MCL cases, and 
these aberrations are thought to play a major role in the develop-
ment and progression of this lymphoma [4, 7, 8]. The 8q24/MYC 
translocation, t(8;14)(q24;q32), has been described as the driv-
ing oncogene in Burkitt’s lymphoma (BL). However, abnormali-
ties in MYC have been recognized in other non-Hodgkin lympho-
mas as well, mainly as a secondary karyotypic change [9]. A few 
cases of MCL with both t(11;14) and MYC rearrangements have 
been reported [10]. To the best of our knowledge, coexistence of 
a complex variant of the t(11;14) and MYC aberrations has not 
been previously reported in Korea. In this study, we report a CD5-
negative blastoid variant of MCL with a rare association of a com-
plex translocation, t(3;11)(q25;p15)t(11;14)(q13;q32) involving 
CCND1, and subclonal MYC aberrations due to t(8;14)(q24;q32).Seok Y, et al.
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 CASE REPORT
An 83-yr-old Korean man was admitted to a university hospital 
for evaluation of leukocytosis, which had been found during an 
examination for spinal stenosis. The initial complete blood count 
results were as follows: hemoglobin level, 10.5 g/dL; platelet 
count, 176×10
9/L; and white blood cell count, 125.8×10
9/L, 
comprising 5% segmented neutrophils, 7% lymphocytes, 2% 
monocytes, 2% myelocytes, 3% metamyelocytes, 2% band 
forms, 3% basophils, 1% atypical lymphocytes, and 75% blast-
like lymphoid cells (medium to large-sized with polymorphous 
nucleus, prominent nucleoli, and a small quantity of basophilic 
cytoplasm) (Fig. 1). Bone marrow aspiration and biopsy analysis 
revealed a normocellular marrow with significant infiltration of 
similar-looking blastoid cells. Immunophenotyping of the bone 
marrow specimens using flow cytometry demonstrated that the 
blastoid cells were positive for CD19, CD20, cCD22, CD23, CD79a, 
HLA-DR, and kappa-restricted surface immunoglobulin, but 
negative for CD5, CD10, and TdT. Chromosome study revealed 
45-47,XY,-9,-11,der(14)t(11;14)(q13;q32),-22,+2~3mar[cp10]/46, 
XY[2] (Fig. 2A). 
  Because the der(14)t(11;14) detected by G-banding gave rise 
to the suspicion that a cryptic t(11;14) might be present, FISH 
was performed using dual-color dual-fusion BCL1 (11q13) green/ 
IGH (14q32) orange probes (Kreatech Diagnostics, Amsterdam, 
the Netherlands). The FISH analysis revealed “nuc ish (BCL1×
3),(IGH×4),(BCL1 con IGH×2)[97/300]/(BCL1,IGH)×3,(BCL1 
con IGH ×2)[93/300]/(BCL1 ×2),(IGH ×3),(BCL1 con IGH ×1)
[31/300]/(BCL1,IGH)×2(BCL1 con IGH×1)[14/300],” showing 
that more than 60% of the cells harbored 2 BCL1/IGH fused sig-
nals representing the 2 derivatives (Fig. 2D). These findings 
were most compatible with the blastoid variant of MCL. To fur-
ther characterize the marker chromosomes and identify another 
submicroscopic CCND1/IGH rearrangement that was undetect-
able by the G-banding technique, multicolor FISH (mFISH) anal-
ysis was performed with a human 24XCyte probe (MetaSystems, 
Altlussheim, Germany). Hybridization and post-hybridization 
washes were performed according to the protocols provided by 
the manufacturers. Image acquisition, processing, and evalua-
tion were performed under a fluorescence microscope (Carl 
Zeiss MicroImaging GmbH, Jena, Germany) by using Isis/mFISH 
imaging software (MetaSystems). mFISH analysis revealed de-
rivative chromosomes, der(11)t(3;11)(q25;p15)t(11;14)(q13;q32), 
der(17)t(8;17)(q?;q?), and der(14)t(8;14)(q24;q32) in 3 meta-
phase cells (Fig. 2B, C). This result led us to conclude that the 2 
marker chromosomes seen in G-banded metaphases were de-
rived from the complex translocation t(11;14) additionally involv-
ing chromosome 3 and the translocation between 8q and 17q.
  The status of the MYC/IGH rearrangement t(8;14) was con-
firmed using FISH with a dual-color dual-fusion MYC (8q24) 
green/IGH (14q32) orange probe (Kreatech Diagnostics). Abnor-
mal patterns with 1 fusion signal were observed in 61% of total 
cells analyzed. The patient was treated with cytarabine, hydroxy-
urea, vincristine, and dexamethasone. However, he was refrac-
tory to chemotherapy and died 28 days after admission.
 
DISCUSSION
The CCND1/IGH gene rearrangement is the most important fac-
tor in the diagnosis of MCL, and the microscopic or submicro-
scopic translocations resulting in complex t(11;14) translocations 
have only been reported in a few MCL cases [5, 8, 11]. MYC 
overexpression is significantly associated with negative prognos-
tic influence, more aggressive phenotypes, lower response rates, 
and shorter overall survival in non-BL patients [9]. The coexis-
tence of complex t(11;14), involving additional partner chromo-
somes and MYC rearrangement, has been previously reported 
[5, 8, 11]. Although the presence of multiple chromosome ab-
normalities in addition to t(11;14) is well known to be associated 
with blastoid variants and poor prognoses in MCL [12], cases re-
ported with complex t(11;14) and MYC overexpression have 
tended to show an accelerated course [10, 13-15] (Table 1). The 
activation of MYC may have a synergistic effect in the MCL pro-
gression [16]. In addition, deletions in chromosome 9, consis-
Fig. 1. The peripheral blood smear shows an increased number of 
medium- to large-sized blastoid cells with polymorphous nuclei and 
basophilic cytoplasm (Wright–Giemsa stain, ×1,000). Seok Y, et al.
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tently detected in this case, are also associated with poor prog-
nosis in MCL [17]. 
  In the present case, conventional cytogenetic analysis pro-
vided evidence of 2 marker chromosomes of unknown origin 
and a translocation t(11;14) (Fig. 2A), and FISH analysis revealed 
2 BCL1/IGH fusion signals (Fig. 2D). mFISH analysis was em-
ployed to define the discrepancy between the 2 methods, and it 
revealed that 1 of the marker chromosomes was a derivative 
chromosome 11, formed by 14q32 fused to 11q13, and the 
11p15 end fused to 3q25, which probably caused another fusion 
signal in the FISH analysis (Fig. 2B). MCL is one of the malig-
nant lymphoid neoplasms with the highest level of clonal hetero-
Table 1. Summary of reported cases of concomitant complex CCND1/IGH and MYC aberrations in MCL patients
Case 
number Sex/age Stage Morphology
Karyotype Survival after 
diagnosis References
11q13 8q24
1 M/71 Stage IV Blastoid t(11;19;14)(q13;q13;q32) der(22)t(8;22)  2 months [13]
2 M/52 Stage IV Blastoid
der(19)t(11;14;19;18)
(CCND1;IGH;wcp18)
t(8;14) cryptic NA, died [14]
3 M/58 Stage III Blastoid
der(11)t(11;14)(q13;q32),der(14)
(14pter-->14q32::?::9q13-->9qter)
t(8;9)(q24;q13) NA, died [15]
4 M/83 Stage IV Blastoid
der(11)t(3;11)(q25;p15)t(11;14)
(q13;q32)
der(14)t(8;14)(q24;q32) 1 month Present case
Abbreviation: NA, not available.
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Fig. 2. (A) Giemsa-banding karyogram of bone marrow cells: 45-47,XY,-9,-11,der(14)t(11;14)(q13;q32),-22,+2~3mar. M1 and M2 indi-
cate marker chromosome 1 and 2, respectively. (B) Single color galleries of mFISH analysis showing der(14)t(11;14)(q13;q32), der(11)
t(3;11)(q25;p15)t(11;14)(q13;q32), der(14)t(8;14)(q24.1;q32), and der(17)t(8;17)(q?;q?) respectively. (C) Diagrammatic representation of 
der(11)t(3;11)(q25;p15)t(11;14)(q13;q32). The arrows indicate breakpoints in chromosomes 3, 11, and 14. (D) FISH analysis using a du-
al-color dual-fusion BCL1(green)/IGH(orange) probe, a subclone harboring 2 fusion (F), 1 BCL1(G) and 2 IGH (R) signals. The correspond-
ing chromosomes are marked as F, G, and R on the karyogram (A).Seok Y, et al.
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geneity, which is indicative of a multistep process of lymphoma-
genesis [8]. Although every G-banded metaphase cell harbored 
derivative chromosomes 11 and 14, representing the population 
showing 2 BCL1/IGH fusion signals in FISH, FISH results showed 
heterogeneous populations of cells; about 10% of total analyzed 
cells that showed 1 BCL1/IGH fusion signal and they can be a 
subclone harboring unbalanced t(11;14). The lack of variation in 
metaphase G-banding could be due to its lower sensitivity com-
pared with interphase FISH analysis, or to the mitotic error of 
subclones with unbalanced and more complex karyotypes, or 
perhaps both. 
  The mFISH is a powerful tool that facilitates the karyotyping of 
complex chromosomal rearrangements, cryptic translocations, 
and marker chromosomes not identifiable by conventional cyto-
genetics. In this study, mFISH complemented G-banding by 
identifying several derivative chromosomes. However, it did not 
clarify the juxtaposition of 14q32 on der(11) and the translocated 
region of 14qter on chromosome 8 (Fig. 2B). This is attributed 
to the resolution limit of mFISH, which has been reported to 
range from 500 to 1,500 kb [18]. The presence of these translo-
cations was completely identified by FISH analyses. 
  Although the immunophenotype of MCL is relatively charac-
teristic, immunophenotypic heterogeneity in MCL has been de-
scribed in blastoid variants, including the absence of CD5 and 
the expression of CD10, BCL6, and CD23 [19, 20]. In conclusion, 
we report a rare case of MCL, with coexistence of a complex 
t(11;14) translocation involving CCND1 and MYC aberrations in 
the blastoid variant of MCL, atypically lacking in CD5 expression. 
The combination of mFISH and FISH with conventional karyo-
typing has enabled the elucidation of the compex chromosomal 
aberrations.
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